Literature DB >> 33479451

Association of proportion of the HDL-cholesterol subclasses HDL-2b and HDL-3 and macrovascular events among patients undergoing hemodialysis.

Wen-Chin Lee1, Jin-Bor Chen2, Sin-Hua Moi3, Cheng-Hong Yang4.   

Abstract

Altered high-density lipoprotein cholesterol (HDL-C) subclass distribution in hemodialysis (HD) patients is well documented. Aim of this study is to investigate the relationship between HDL-C subclass distribution and macrovascular events in patients undergoing HD. A total of 164 prevalent HD patients and 71 healthy individuals in one hospital-facilitated clinic were enrolled from May 2019 to July 2019 and individual HD patients was follow-up for one year. Macrovascular events (cerebral stroke, coronary heart disease) were recorded in the study period. The HDL-2b, HDL-3 proportions and biochemical parameters were measured. Pearson correlation test and logistic regression analysis were used to examine correlation and odds ratio (OR). 144 HD patients completed one-year follow-up. Cohort with macrovascular events revealed significantly lower HDL-2b and higher HDL-3 subclass proportions compared to those without events. By multivariable adjustment, HDL-3 subclass proportion revealed significantly increase risk for these events (OR 1.17, 95% CI 1.02-1.41, P = 0.044). HDL-2b subclass was significantly higher and HDL-3 subclass was significantly lower in the HD cohort under the hs-CRP level of < 3 mg/L compared to higher hs-CRP level. In conclusion, HDL-2b and HDL-3 subclasses distributions were associated with macrovascular events in HD patients. Proinflammatory status influences the distribution of HDL-2b and HDL-3 subclasses in HD patients.

Entities:  

Year:  2021        PMID: 33479451     DOI: 10.1038/s41598-021-81636-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  39 in total

1.  Cardiovascular disease and chronic renal disease: a new paradigm.

Authors:  M J Sarnak; A S Levey
Journal:  Am J Kidney Dis       Date:  2000-04       Impact factor: 8.860

2.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Authors:  Alberico L Catapano; Ian Graham; Guy De Backer; Olov Wiklund; M John Chapman; Heinz Drexel; Arno W Hoes; Catriona S Jennings; Ulf Landmesser; Terje R Pedersen; Željko Reiner; Gabriele Riccardi; Marja-Riita Taskinen; Lale Tokgozoglu; W M Monique Verschuren; Charalambos Vlachopoulos; David A Wood; Jose Luis Zamorano; Marie-Therese Cooney
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

3.  Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients.

Authors:  Tae Ik Chang; Elani Streja; Melissa Soohoo; Gang Jee Ko; Connie M Rhee; Csaba P Kovesdy; Moti L Kashyap; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Hamid Moradi
Journal:  J Clin Lipidol       Date:  2018-01-31       Impact factor: 4.766

Review 4.  Dyslipidemia in patients with chronic kidney disease.

Authors:  Matthew R Hager; Archana D Narla; Lisa R Tannock
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

5.  Risk Factors and Outcomes of Cerebral Stroke in End-Stage Renal Disease Patients Receiving Hemodialysis.

Authors:  Yuki Shinya; Satoru Miyawaki; Isao Kumagai; Takehiro Sugiyama; Atsumi Takenobu; Nobuhito Saito; Akira Teraoka
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-02-07       Impact factor: 2.136

Review 6.  2017 Taiwan lipid guidelines for high risk patients.

Authors:  Yi-Heng Li; Kwo-Chang Ueng; Jiann-Shing Jeng; Min-Ji Charng; Tsung-Hsien Lin; Kuo-Liong Chien; Chih-Yuan Wang; Ting-Hsing Chao; Ping-Yen Liu; Cheng-Huang Su; Shih-Chieh Chien; Chia-Wei Liou; Sung-Chun Tang; Chun-Chuan Lee; Tse-Ya Yu; Jaw-Wen Chen; Chau-Chung Wu; Hung-I Yeh
Journal:  J Formos Med Assoc       Date:  2017-02-24       Impact factor: 3.282

7.  Association between serum lipids and survival in hemodialysis patients and impact of race.

Authors:  Ryan D Kilpatrick; Charles J McAllister; Csaba P Kovesdy; Stephen F Derose; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  J Am Soc Nephrol       Date:  2006-12-13       Impact factor: 10.121

8.  HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients.

Authors:  Günther Silbernagel; Bernd Genser; Christiane Drechsler; Hubert Scharnagl; Tanja B Grammer; Tatjana Stojakovic; Vera Krane; Eberhard Ritz; Christoph Wanner; Winfried März
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

Review 9.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Hypertension       Date:  2003-11       Impact factor: 10.190

Review 10.  Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.

Authors:  Ron T Gansevoort; Ricardo Correa-Rotter; Brenda R Hemmelgarn; Tazeen H Jafar; Hiddo J Lambers Heerspink; Johannes F Mann; Kunihiro Matsushita; Chi Pang Wen
Journal:  Lancet       Date:  2013-05-31       Impact factor: 79.321

View more
  2 in total

1.  Lipoprotein Subclasses Independently Contribute to Subclinical Variance of Microvascular and Macrovascular Health.

Authors:  Lukas Streese; Hansjörg Habisch; Arne Deiseroth; Justin Carrard; Denis Infanger; Arno Schmidt-Trucksäss; Tobias Madl; Henner Hanssen
Journal:  Molecules       Date:  2022-07-25       Impact factor: 4.927

Review 2.  The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets.

Authors:  Siarhei A Dabravolski; Victoria A Khotina; Andrey V Omelchenko; Vladislav A Kalmykov; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.